Search
Jul 3
Mereo BioPharma’s CEO discusses recent setrusumab data in Osteogenesis Imperfecta and the future of alvelestat
Denise Scots-Knight describes what Mereo and its partner Ultragenyx have seen in setrusumab data over time, and her description of the...